[go: up one dir, main page]

WO1998006749B1 - Proteines de fusion de classe ii du cmh, solubles, monovalentes ou polyvalentes, et utilisations associees - Google Patents

Proteines de fusion de classe ii du cmh, solubles, monovalentes ou polyvalentes, et utilisations associees

Info

Publication number
WO1998006749B1
WO1998006749B1 PCT/US1997/014503 US9714503W WO9806749B1 WO 1998006749 B1 WO1998006749 B1 WO 1998006749B1 US 9714503 W US9714503 W US 9714503W WO 9806749 B1 WO9806749 B1 WO 9806749B1
Authority
WO
WIPO (PCT)
Prior art keywords
class
mhc class
major histocompatibility
fusion protein
histocompatibility complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/014503
Other languages
English (en)
Other versions
WO1998006749A2 (fr
WO1998006749A3 (fr
Filing date
Publication date
Priority to EP97938386A priority Critical patent/EP0935607B1/fr
Priority to AT97938386T priority patent/ATE272070T1/de
Priority to JP10510100A priority patent/JP2000516470A/ja
Priority to DE69730038T priority patent/DE69730038T2/de
Priority to CA002263195A priority patent/CA2263195A1/fr
Priority to AU40723/97A priority patent/AU730457B2/en
Application filed filed Critical
Priority to NZ333915A priority patent/NZ333915A/xx
Publication of WO1998006749A2 publication Critical patent/WO1998006749A2/fr
Publication of WO1998006749A3 publication Critical patent/WO1998006749A3/fr
Publication of WO1998006749B1 publication Critical patent/WO1998006749B1/fr
Anticipated expiration legal-status Critical
Priority to US10/895,543 priority patent/US20050003431A1/en
Ceased legal-status Critical Current

Links

Abstract

La présente invention concerne le domaine de l'immunologie. Elle se rapporte notamment à la conception, à la production et à l'utilisation de protéines de fusion recombinées dérivées, en partie, des protéines du complexe majeur d'histocompatibilité (CMH) humain.
PCT/US1997/014503 1996-08-16 1997-08-15 Proteines de fusion de classe ii du cmh, solubles, monovalentes ou polyvalentes, et utilisations associees Ceased WO1998006749A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
NZ333915A NZ333915A (en) 1996-08-16 1997-08-15 Soluble monovalent and multivalent MHC class II fusion proteins
AT97938386T ATE272070T1 (de) 1996-08-16 1997-08-15 Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
JP10510100A JP2000516470A (ja) 1996-08-16 1997-08-15 可溶性一価および多価ｍｈｃクラスｉｉ融合タンパク質およびそれらの使用
DE69730038T DE69730038T2 (de) 1996-08-16 1997-08-15 Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
CA002263195A CA2263195A1 (fr) 1996-08-16 1997-08-15 Proteines de fusion de classe ii du cmh, solubles, monovalentes ou polyvalentes, et utilisations associees
EP97938386A EP0935607B1 (fr) 1996-08-16 1997-08-15 Proteines de fusion de classe ii du cmh, solubles, monovalentes ou polyvalentes, et utilisations associees
AU40723/97A AU730457B2 (en) 1996-08-16 1997-08-15 Soluble monovalent and multivalent MHC class II fusion proteins, and uses therefor
US10/895,543 US20050003431A1 (en) 1996-08-16 2004-07-21 Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2407796P 1996-08-16 1996-08-16
US60/024,077 1996-08-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/895,543 Continuation-In-Part US20050003431A1 (en) 1996-08-16 2004-07-21 Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor

Publications (3)

Publication Number Publication Date
WO1998006749A2 WO1998006749A2 (fr) 1998-02-19
WO1998006749A3 WO1998006749A3 (fr) 1998-06-11
WO1998006749B1 true WO1998006749B1 (fr) 1998-07-16

Family

ID=21818743

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/014503 Ceased WO1998006749A2 (fr) 1996-08-16 1997-08-15 Proteines de fusion de classe ii du cmh, solubles, monovalentes ou polyvalentes, et utilisations associees

Country Status (11)

Country Link
EP (1) EP0935607B1 (fr)
JP (1) JP2000516470A (fr)
AT (1) ATE272070T1 (fr)
AU (1) AU730457B2 (fr)
CA (1) CA2263195A1 (fr)
DE (1) DE69730038T2 (fr)
DK (1) DK0935607T3 (fr)
ES (1) ES2221065T3 (fr)
NZ (1) NZ333915A (fr)
PT (1) PT935607E (fr)
WO (1) WO1998006749A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
WO1997035991A1 (fr) 1996-03-28 1997-10-02 The Johns Hopkins University Analogues solubles heterodimeres divalents et multivalents de proteines
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
JP2002504342A (ja) * 1998-02-19 2002-02-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 一価ｍｈｃ結合ドメイン融合タンパク質および接合体、多価ｍｈｃ結合ドメイン融合タンパク質および接合体、ならびに多量体ｍｈｃ結合ドメイン融合タンパク質および接合体、そしてそれらのための使用
FR2778669B1 (fr) * 1998-05-14 2002-06-14 Centre Nat Rech Scient Procede d'expression d'un complexe forme d'au moins un produit du complexe majeur d'histocompatibilite et d'un peptide chez un phage, phages et complexes ainsi obtenus et leurs applications
KR100530309B1 (ko) * 1998-05-19 2005-11-22 아비덱스 리미티드 가용성 ｔ 세포 수용체
FR2796953B1 (fr) * 1999-07-29 2003-10-10 Centre Nat Rech Scient Proteines recombinantes, et complexes moleculaires derives de ces proteines, analogues a des molecules impliquees dans les reponses immunitaires
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
CA2433194C (fr) 2000-10-10 2012-04-03 The Board Of Regents Of The University Of Oklahoma Mappage comparatif de ligand a partir de cellules positives cmh
IL156473A0 (en) * 2000-12-18 2004-01-04 Univ Oklahoma Method and apparatus for the production of antigens
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US7094555B2 (en) 2001-04-05 2006-08-22 Benaroya Research Institute At Virginia Mason Methods of MHC class II epitope mapping, detection of autoimmune T cells and antigens, and autoimmune treatment
WO2009003492A1 (fr) 2007-07-03 2009-01-08 Dako Denmark A/S Procédés améliorés pour produire, marquer et utiliser des multimères du cmh
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
ES2559763T3 (es) * 2002-09-10 2016-02-15 Affimed Gmbh Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
JP5452835B2 (ja) * 2003-07-15 2014-03-26 中外製薬株式会社 形質転換細胞によるＩｇＭの産生とその定量方法
ATE518888T1 (de) 2003-10-09 2011-08-15 Chugai Pharmaceutical Co Ltd Stabilisierte lösung mit hoher igm-konzentration
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
EP2361930A3 (fr) 2007-03-26 2011-10-26 Dako Denmark A/S Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia
WO2009039854A2 (fr) 2007-09-27 2009-04-02 Dako Denmark A/S Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (fr) 2008-07-23 2010-01-28 Dako Denmark A/S Analyse et réparation combinatoires
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (fr) 2008-10-02 2010-04-08 Dako Denmark A/S Vaccins moléculaires contre les maladies infectieuses
GB201002730D0 (en) 2010-02-18 2010-04-07 Uni I Oslo Product
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
KR20140114859A (ko) * 2012-01-06 2014-09-29 오레곤 헬스 앤드 사이언스 유니버시티 부분적 mhc 구축물 및 이의 사용 방법
EP2817625B1 (fr) 2012-02-23 2025-01-01 Juno Therapeutics GmbH Isolement chromatographique des cellules et d'autres materiaux biologiques complexes
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US10316075B2 (en) 2013-10-03 2019-06-11 Oregon Health & Science University Recombinant polypeptides comprising MHC class II α1 domains
EP3539564A1 (fr) 2013-11-04 2019-09-18 UTI Limited Partnership Méthodes et compositions d'immunothérapie soutenue
WO2015148960A1 (fr) 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprenant des complexes hla soluble/ligand spécifique à m. tuberculosis et procédés de production et d'utilisation de ces dernières
CN113549153A (zh) 2014-05-29 2021-10-26 宏观基因有限公司 三特异性结合分子和其使用方法
US11585806B2 (en) 2014-06-13 2023-02-21 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
SG10201913957PA (en) 2015-05-06 2020-03-30 Uti Lp Nanoparticle compositions for sustained therapy
IL258521B2 (en) 2015-10-08 2024-01-01 Macrogenics Inc Combination therapy for the treatment of cancer
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
CA3042615A1 (fr) * 2016-11-09 2018-05-17 Uti Limited Partnership Molecules de classe ii de pmhc de recombinaison
EP3615653B1 (fr) 2017-04-27 2025-07-23 Juno Therapeutics, Inc. Reactifs particulaires oligomères et leurs méthodes d'utilisation
CA3083748A1 (fr) 2017-11-29 2019-06-06 Uti Limited Partnership Methodes de traitement d'une maladie auto-immune
WO2020018715A1 (fr) * 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Protéines de fusion à base d'échafaudage d'immunoglobuline multimère soluble et leurs utilisations
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
CN112816595A (zh) * 2021-01-06 2021-05-18 海默斯（重庆）医学生物技术有限公司 一种重组角蛋白液体制剂及其纯度检测方法
WO2022216974A1 (fr) * 2021-04-07 2022-10-13 Repertoire Immune Medicines, Inc. Multimères de peptide-mhc-immunoglobuline et leurs procédés d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3220593A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
ES2152424T5 (es) * 1994-07-29 2010-07-05 Sunol Molecular Corporation Complejos del mhc y usos de los mismos.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells

Similar Documents

Publication Publication Date Title
WO1998006749B1 (fr) Proteines de fusion de classe ii du cmh, solubles, monovalentes ou polyvalentes, et utilisations associees
Schumacher et al. Peptide selection by MHC class I molecules
Hackeng et al. Total chemical synthesis of human matrix Gla protein
EP2298331A3 (fr) Utilisation de fusions de peptides/protéines de transthyrétine pour augmenter la demi-vie sérique de peptides/protéines pharmacologiquement actifs
Bailey et al. Partial characterization of a second basement membrane collagen in human placenta: evidence for the existence of two type IV collagen molecules
CA2265900A1 (fr) Amelioration apportee a une synthese de peptides en phase solide et agent utilise dans ladite synthese
ATE257160T1 (de) Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde
CA2148383A1 (fr) Inhibiteurs peptidiques pour fibronectine et proteines apparentees fixees au collagene
EP0873754A4 (fr) Compositions d'acides amines
WO2006101782A3 (fr) Etiquette peptidique contenant une cysteine pour conjugaison de proteines specifique d'un site
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
König et al. The amino acid sequence of the peptide moiety of the pseudomurein from Methanobacterium thermoautotrophicum
Tirindelli et al. Complete amino acid sequence of pyrazine‐binding protein from cow nasal mucosa
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
TAKAGI et al. Amino acid sequence of troponin C obtained from ascidian (Halocynthia roretzi) body wall muscle
IE800053L (en) Muraminyl polypeptides
Araki et al. The position of the disulfide bonds in human plasma α2HS-glycoprotein and the repeating double disulfide bonds in the domain structure
Futaki et al. Embodying a stable α-helical protein structure through efficient chemical ligation via thioether formation
WO1994026903A3 (fr) Peptides du virus de la grippe chez l'homme se fixant a une molecule de hla-i
GB9917725D0 (en) Peptides
SI2952521T1 (en) Peptides derived from human BPLP protein, polynucleotides encoding these peptides, and antibodies directed against these peptides
EP0794255A3 (fr) Procédé de clivage d'une protéine chimérique à l'aide d'un enzyme de traitement
WO1999002708A8 (fr) Proteines de fusion comprenant des structures bispiralees derivees de la proteine inhibitrice de if1 atpase bovine
WO1999048908A3 (fr) POLYPEPTIDE IMMUNOREACTIF DU RECEPTEUR TrkA du NGF ET UTILISATIONS
NZ335136A (en) Isolated peptides which complex with hla-cw*16 molecules, and uses thereof